VOLUME 60   1999   SUPPLEMENT 19

Articles

3 Introduction. Antipsychotic Agents: Clinical, Economic, and Legal Considerations in the Treatment of Psychosis.
Anthony F. Lehman, M.D., M.S.P.H.
[PDF]

5 Use Patterns for Antipsychotic Medications in Medicaid Patients With Schizophrenia. Jeffrey S. McCombs, Ph.D.; Michael B. Nichol, Ph.D.; Glen L. Stimmel, Pharm.D.; Jinhai Shi, M.S.; and Raymond R. Smith, Pharm.D.
[Abstract] [PDF]

14 Annual Health Outcomes and Treatment Costs for Schizophrenia Populations. Josephine A. Mauskopf, Ph.D.; Kevin David; David L. Grainger; and P. Joseph Gibson, Ph.D.
[Abstract] [PDF]

23 Compliance and the Rehabilitation Alliance. Ralph Aquila, M.D.; Peter J. Weiden, M.D.; and Marianne Emanuel, R.N.
[Abstract] [PDF]

30 Developing an Outcomes-Oriented Approach for the Treatment of Schizophrenia. Anthony F. Lehman, M.D., M.S.P.H.
[Abstract] [PDF]

38 Changes in Perceived Health and Functioning as a Cost-Effectiveness Measure for Olanzapine Versus Haloperidol Treatment of Schizophrenia. Sandra L. Tunis, Ph.D.; Bryan M. Johnstone, Ph.D.; P. Joseph Gibson, Ph.D.; Danielle L. Loosbrock, M.H.A.; and Brian K. Dulisse, Ph.D.
[Abstract] [PDF]

47 Effectiveness of Combining Atypical Antipsychotics and Psychosocial Rehabilitation in a Community Mental Health Center Setting. Douglas L. Noordsy, M.D., and Christopher O’Keefe, M.A.
[Abstract] [PDF]

54 The Role of Neuropsychiatric Pharmacists. Lawrence J. Cohen, Pharm.D., B.C.P.P., F.A.S.H.P., F.C.C.P.
[Abstract] [PDF]

59 Legal and Ethical Considerations in the Treatment of Psychosis. Walter L. Fitzgerald, Jr., B.S.Pharm., M.S., J.D.
[Abstract] [PDF]

CME Section

67 Instructions and Posttest.
[PDF]